Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to Develop Therapies Targeting Schizophrenia

 Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to Develop Therapies Targeting Schizophrenia

Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to Develop Therapies Targeting Schizophrenia

Shots:

  • Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research, develop, manufacture and commercialize therapeutics, identified under the collaboration
  • The focus of the collaboration is to identify new therapies for schizophrenia by utilizing Saniona’s ion channel drug discovery platform
  • Saniona will receive funding during the research period and anticipates $0.49M funding, during the first year of collaboration. In 2016, the companies collaborated to develop therapies for schizophrenia, targeting GABA α5 ion channels to treat cognitive impairment with its first program, currently in the preclinical stage

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post